Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Glycorex Transplantation

1,82 SEK

+0,28 %

Mindre end 1K følgere

GTAB B

NGM Main Regulated

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,28 %
-11,22 %
-13,74 %
-17,65 %
-10,78 %
+21,33 %
-59,56 %
-86,91 %
-82,07 %

Glycorex Transplantation is active in biotechnology. The company conducts research, development and marketing in the field of organ transplantation. The company's main product enables transplants regardless of the blood type of the donor or recipient. Transplantation using the company's product is carried out on a global level. Glycorex Transplantation was founded in 1996 and has its headquarters in Lund.

Læs mere
Markedsværdi
143,51 mio. SEK
Aktieomsætning
78,83 t SEK
Omsætning
35,16 mio.
EBIT %
-29,69 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
28.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse13.8.2025, 10.50

Glycorex Transplantation (GTAB B): First ABO-incompatible organ transplantion in Morocco with Glycosorb® ABO

Glycorex Transplantation
Pressemeddelelse28.2.2025, 08.06

Glycorex Transplantation (GTAB B): Enters distribution agreement in Greece for Glycosorb® ABO in the field of transfusion and transplantation

Glycorex Transplantation
Pressemeddelelse18.2.2025, 14.26

Glycorex Transplantation AB: First ABO-incompatible transplantation in Portugal with Glycosorb® ABO

Glycorex Transplantation

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse23.12.2024, 07.30

Glycorex Transplantation AB (GTAB B): First blood group-incompatible pediatric heart transplantation in Austria using Glycosorb® ABO

Glycorex Transplantation
Pressemeddelelse13.9.2024, 09.15

Glycorex Transplantation AB (GTAB B): Results from Norwegian platelet evaluation presented at conference

Glycorex Transplantation
Pressemeddelelse13.8.2024, 08.00

Glycorex Transplantation AB: First ABO-incompatible transplantation in Argentina with Glycosorb® ABO

Glycorex Transplantation
Pressemeddelelse13.5.2024, 06.20

Glycorex Transplantation: Glycosorb® ABO is pushing the boundaries in paediatric blood group incompatible heart transplantation

Glycorex Transplantation
Pressemeddelelse8.5.2024, 11.24

Glycorex Transplantation: First publication from South Africa and first stem cell transplantation performed in Mexico

Glycorex Transplantation
Pressemeddelelse20.2.2024, 11.39

Glycorex Transplantation (GTAB B): Signs agreement with distributor in Romania

Glycorex Transplantation
Selskabsmeddelelse29.11.2023, 09.31

Glycorex Transplantation AB: Entering into an agreement with Bio-Rad Laboratories, Inc.

Glycorex Transplantation
Selskabsmeddelelse29.11.2023, 07.00

Glycorex Transplantation AB (publ): Interim Report January - September 2023

Glycorex Transplantation
Selskabsmeddelelse30.8.2023, 06.00

Glycorex Transplantation AB (publ): Interim Report January - June 2023

Glycorex Transplantation
Selskabsmeddelelse24.5.2023, 06.00

Glycorex Transplantation AB (publ): Interim Report January - March 2023

Glycorex Transplantation
Selskabsmeddelelse28.4.2023, 16.00

Annual Report 2022 Glycorex Transplantation AB (publ)

Glycorex Transplantation
Pressemeddelelse9.3.2023, 14.00

Glycorex Transplantation: Published study from the US shows promising results on the use of Glycosorb® ABO to provide low-titer group O whole blood

Glycorex Transplantation
Selskabsmeddelelse28.2.2023, 07.00

Glycorex Transplantation: Year-end Report 2022

Glycorex Transplantation
Pressemeddelelse20.2.2023, 11.00

Glycorex Transplantation: The first blood group incompatible kidney transplant using Glycosorb® ABO performed in South Africa

Glycorex Transplantation
Pressemeddelelse31.1.2023, 15.00

Glycorex Transplantation: Glycorex strengthens the organization to place additional force behind the growth strategy Going 4 Growth

Glycorex Transplantation
Selskabsmeddelelse24.11.2022, 07.00

Glycorex Transplantation AB (GTAB B): Interim report January - September 2022

Glycorex Transplantation
Pressemeddelelse27.9.2022, 13.23

Glycorex Transplantation (GTAB B): Glycosorb[®] ABO used at the largest heart transplant center in Germany

Glycorex Transplantation
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.